Drug Designing is the method in which the drugs are designed based on their biological target. This method helps the human race for therapeutic uses.
Total number of patents granted for this method is 19 patents. Some of the methods patented are given below.
Patent no: 6,703,486 titled ‘Peripheral nervous system specific sodium channels’ with the abstract: Cloning, expression, viral and delivery vectors and hosts which contain nucleic acid coding for at least one peripheral nervous system specific (PNS) sodium channel peptide (SCP), isolated PNS SCP, and compounds and compositions and methods, are provided, for isolating, crystallizing, x-ray analysing molecular modeling, rational drug designing, selecting, making and using therapeutic or diagnostic agents or ligands having at least one peripheral nervous system specific (PNS) sodium channel (SC) modulating activity.
Patent no: 6,132,988 titled ‘DNA encoding a neuronal cell-specific receptor protein’ with the abstract : To provide a method of isolating and detecting a new receptor gene, as a means of elucidating the function of neuronal cell-specific receptors, especially of elucidating the detailed mechanism of the neuronal cell differentiation inhibitory and nerve nutrition factor-like actions of activin receptors, DNA containing said new receptor gene, a method of producing a protein encoded by this new receptor gene, and use for this DNA and protein. The receptor protein of the present invention and DNA encoding this protein can be used for various purposes, including 1) ligand determination, 2) obtainment of antibodies and antisera, 3) construction of recombinant receptor protein expression systems, 4) development of receptor binding assay systems and screening for pharmaceutical candidate compounds using expression systems, 5) drug designing based on comparison with structurally similar ligand receptors, 6) reagent for preparation of probes and PCR primers for gene diagnosis, and 7) drug for gene therapy.
Patent no: 6,110,672 titled ‘Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, X-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof’ with the abstract : Cloning, expression, viral and delivery vectors and hosts which contain nucleic acid coding for at least one peripheral nervous system specific (PNS) sodium channel peptide (SCP), isolated PNS SCP, and compounds and compositions and methods, are provided, for isolating, crystallizing, x-ray analysing molecular modeling, rational drug designing, selecting, making and using therapeutic or diagnostic agents or ligands having at least one peripheral nervous system specific (PNS) sodium channel (SC) modulating activity.
Patent no: 6,610,675 titled ‘Inactive metabolite approach to soft drug design’ with the abstract: The invention provides novel soft steroidal anti-inflammatory agents, pharmaceutical compositions containing said agents, and methods of administering same to mammals in the treatment of inflammation. Preferred compounds of the invention include haloalkyl 17.alpha.-alkoxycarbonyloxy-11.beta.-hydroxyandrost-4-en-3-one-17.beta.-ca rboxylates and the corresponding .DELTA..sup.1,4 compounds, optionally bearing 6.alpha.- and/or 9.alpha.-fluorine and 16.alpha.- or 16.beta.-methyl substituents. Especially preferred compounds include haloalkyl 17.alpha.-alkoxycarbonyloxy-9.alpha.-fluoro-11.beta.-hydroxy-16-methylandr osta-1,4-dien-3-one-17.beta.-carboxylates.
Join Free Patent Lessons Course
